Adenocard Shortage: What Providers and Prescribers Need to Know in 2026

Adenosine injection (Adenocard) is a critical cardiac drug that emergency departments, cardiology practices, nuclear medicine departments, and EMS services rely on daily. Despite the absence of a formal FDA-declared national shortage as of 2026, supply variability at the distributor level is a persistent operational reality. For providers and pharmacy teams, understanding the supply landscape and having a structured shortage management protocol is not optional — it is essential to patient safety.

This clinical guide is designed for emergency physicians, cardiologists, intensivists, pharmacists, and advanced practice providers who need practical, actionable guidance on managing adenosine supply disruptions in 2026.

Current Supply Status: What the Data Shows

As of early 2026, adenosine injection (3 mg/mL) is not listed on the FDA Drug Shortage Database as a nationally declared shortage. Generic adenosine is manufactured by multiple companies including Pfizer Injectables, Hikma, Fresenius Kabi, and others, which provides a degree of supply redundancy not available for single-source drugs.

However, injectable sterile drug supply remains structurally fragile in the U.S. system. Research published by IQVIA found that as of mid-2024, the FDA had over 100 active drug shortages, with more than half lasting longer than two years. Adenosine's history of shortage vulnerability — particularly during the 2011–2012 injectable drug crisis — means providers should maintain active vigilance rather than assuming current non-shortage status will persist.

Clinical Indications Affected by an Adenosine Shortage

A disruption in adenosine supply affects two distinct clinical populations and care settings:

1. Emergency PSVT management: Adenosine (Adenocard, 6 mg/2 mL vials) is the AHA first-line agent for converting paroxysmal supraventricular tachycardia, including AV nodal reentrant tachycardia (AVNRT) and AV reentrant tachycardia (AVRT) associated with accessory pathways including WPW syndrome. This is an acute, time-sensitive use in EDs and inpatient settings.
2. Nuclear pharmacologic stress testing: Adenosine (Adenoscan, 20 mL vials at 140 mcg/kg/min for 6 minutes) is used for myocardial perfusion imaging in patients who cannot exercise. Supply disruption here affects outpatient cardiology and nuclear medicine program scheduling.

Shortage Triggers to Watch: Early Warning Signals

Clinical pharmacists and supply chain teams should monitor these indicators as early signs of an emerging adenosine shortage:

• Increasing back-order frequency from primary GPO distributor
• Allocation notices from Cardinal Health, McKesson, or AmerisourceBergen
• ASHP shortage bulletins for adenosine injection
• Manufacturer Dear Healthcare Provider letters
• Peer institution communications about sourcing difficulties

Formulary Management During Adenosine Supply Constraints

When supply tightens, a tiered conservation approach helps protect available stock for the highest-priority uses:

1. Prioritize emergency PSVT stock: Reserve 6 mg/2 mL vials for acute arrhythmia management in the ED and ICU. This is the highest-priority use case.
2. Transition stress testing to regadenoson: Switch nuclear stress testing from adenosine (Adenoscan) to regadenoson (Lexiscan) — a selective A2A agonist given as a single 0.4 mg bolus — for all elective stress testing while supply is constrained.
3. Source alternate NDCs: Contact pharmacy buyers to cross-reference all available adenosine injection NDC numbers across multiple manufacturers and distributors.
4. Activate backup PSVT protocol: Prepare the clinical team to use IV verapamil or IV diltiazem as primary PSVT agents if adenosine stock is critically low.

Evidence-Based Clinical Alternatives for PSVT Management

IV Verapamil: 5 mg IV over 2 minutes (slower in elderly). May repeat 5–7.5 mg in 5–10 min. Max 20 mg total. Contraindicated in WPW, impaired LV function, concurrent beta-blockade. Conversion rate ~90%, equivalent to adenosine.

IV Diltiazem: 0.25 mg/kg (15–20 mg) IV over 2 min; repeat 0.35 mg/kg (25–35 mg) in 15 min if needed. Maintenance infusion 5–15 mg/hour. Half-life ~3 hours. Associated with lower hypotension risk than verapamil in slow-infusion studies. FDA-approved for PSVT.

Key clinical note: Both verapamil and diltiazem are contraindicated in WPW syndrome with pre-excitation due to risk of accelerating conduction over the accessory pathway and precipitating ventricular fibrillation. In patients with known or suspected WPW and hemodynamic instability, synchronized cardioversion is the appropriate intervention.

Patient Communication During a Shortage

For patients with scheduled pharmacologic stress tests, transparent communication is important. Explain that the procedure can proceed with an alternative agent (regadenoson), that the diagnostic value is equivalent, and that the switch is a routine clinical adaptation, not a compromise in care quality. For patients with a history of PSVT, document their adenosine tolerance and any previous adverse reactions (severe chest pain, prolonged asystole, seizure) to inform the choice between adenosine and a calcium channel blocker if both are available.

Resources and Tools for Shortage Management

Providers managing drug supply challenges can use medfinder for providers to identify which pharmacies and distributors near you currently have adenosine injection in stock. medfinder contacts pharmacies directly to verify availability, saving your pharmacy team hours of calls. Additional resources include the ASHP Drug Shortage Resource Center at ashp.org/drug-shortages and the FDA Drug Shortage Database at accessdata.fda.gov.

Summary: Provider Action Checklist

• Monitor ASHP and FDA databases regularly for adenosine shortage signals
• Cross-reference alternate NDCs for generic adenosine with your GPO buyer
• Maintain a written backup protocol for IV verapamil and IV diltiazem
• Transition elective stress testing to regadenoson if adenosine supply is constrained
• Contact secondary wholesalers and use medfinder to locate available stock
• Communicate transparently with patients whose procedures may be affected